Statement
6 Jun 2023
G20 side event on “Envisaging a Global R&D Network for Research in Vaccines, Therapeutics, and Diagnostics (VTDs) to enhance Prevention, Preparedness, and Response (PPR)”
On 6 June, IFPMA delivered a statement at the G20 “Strengthening Global Collaboration on Research and Development in MCMs (Diagnostics, Vaccines, and Therapeutics” side event on “Envisaging a Global R&D Network for Research in VTDs to enhance PPR” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read more
Position paper
12 Apr 2023
Key considerations on the scope, utility and processes around updating the WHO Essential Medicines List
The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.
Read more
Statement
1 Feb 2023
Substandard and falsified medical products (EB152)
On 1 February 2023, IPSF submitted a statement delivered on behalf of IPSF, IAPO, and IFPMA for the WHO EB152 agenda item related to substandard and falsified medical products.
Read more
